OBJECTIVES: Turoctocog Alfa (Novoeight^®), a recombinant factor Ⅷ(rFⅧ), was approved in China in 2021. Product X is the most commonly used rFⅧ product among Chinese patients with haemophilia A. This study was to compare the annual cost between these two products as prophylaxis treatment for paediatric and adult patients with severe haemophilia A from the Chinese healthcare perspective.

METHODS: A cost minimization model was constructed to calculate the total annual costs of Novoeight^® and product X as prophylaxis treatment for paediatric and adult patients with severe haemophilia A. Only drug cost of prophylaxis and breakthrough bleeds treatment during the prophylaxis were included. Mean price of these two products were sourced from the average bidding price in August 2021 in China. Clinical data of mean prophylaxis dosing and annual breakthrough bleed rate were obtained from respective clinical trial that included previously treated patients with severe hemophilia A. Other clinical data, including patient’s weight, proportion and treatment dosing for mild, moderate and severe bleeds were taken from published local data and Chinese package insert. Considering clinical practice in China, scenario analysis was conducted using minimum prophylaxis dosage of each product.

RESULTS: Base case results showed that compared to product X, Novoeight^® prophylaxis was associated with total cost saving of ￥15,127 and ￥82,709 for paediatric patients and adult patients with severe haemophilia A, respectively, including lower costs for prophylaxis and breakthrough bleeds treatment. Scenario analysis also showed that Novoeight^® was associated with lower total annual costs ( -￥59,749 and -￥392,605 for paediatric patients and adult patients, respectively).

CONCLUSIONS: Compared with product X, using Novoeight^® as prophylaxis treatment was likely to reduce the total annual costs both for prophylaxis and breakthrough bleeds treatment in paediatric and adult patients with severe haemophilia A in China.